Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report

Respiratory Medicine Case Reports

Tobias Müller¹  Jens Spiesshoefer²  Ayham Daher²  Jens Panse²  Michael Dreher² 

[1] Corresponding author. Department of Pneumology and Intensive Care Medicine, University Hospital RWTH, Pauwelsstrasse 30, 52074, Aachen, Germany.;Department of Pneumology and Intensive Care Medicine, University Hospital RWTH, Aachen, Germany;

关键词: COVID-19;    Immunodeficiency;    B-Cell aplasia;    Monoclonal antibodies;   

DOI  :  

来源: DOAJ

【 摘 要 】

A 71-year-old female patient with B-cell depletion due to treatment with an anti-CD20 monoclonal antibody was admitted for worsening COVID-19. Overall, she had persistent viral shedding, worsening respiratory failure, and progressive pneumonia that did not improve despite dexamethasone and antibiotic therapy. After administration of bamlanivimab, a monoclonal antibody with high affinity for the receptor-binding domain of the SARS-CoV-2 spike protein, inflammatory markers rapidly decreased, SARS-CoV2 RT-PCR became negative, and the patient improved clinically and radiologically. In conclusion, we demonstrated successful treatment of prolonged COVID-19 in a patient with severe B-cell aplasia with a virus-neutralizing monoclonal antibody.

【 授权许可】

Unknown